publication date: Feb. 2, 2018
Conversation with the Cancer Letter Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”
Chief medical officer of Foundation Medicine Inc
Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.
“I think doctors and patients have tremendous confidence in knowing that a test has gone through the scrutiny of FDA review,” Miller said to The Cancer Letter. “It offloads some of the thinking they need to do as they sit there with a patient and there are multiple issues on the table in a very short period of time to be addressed in which to see the patient.
“This becomes, I believe, indispensable to an important aspect of cancer care for patients with advanced or metastatic disease—selection of the most rational therapy.”
Miller spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
First of all, what does this approval mean for the field of precision medicine?
Continue reading Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.